Amgen (id:7057 AMGN)
262.84 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 12/23/2024 2:22:31 PM)
Exchange open, closes in 1 hour 37 minutes
About Amgen
Market Capitalization 142.89B
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
| Headquarters (address) |
One Amgen Center Drive Thousand Oaks 91320-1799 CA United States |
| Phone | 805 447 1000 |
| Website | https://www.amgen.com |
| Employees | 27K |
| Sector | Healthcare |
| Industry | Drug Manufacturers General |
| Ticker | AMGN |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 253.30 - 346.85 |
| Market Capitalization | 142.89B |
| Dividend yield forward | 3.42 % |
| Dividend yield forward United States (ID:6, base:1858) | 4.48 % |
| P/E trailing | 33.91 |
| P/E forward | 12.86 |
| Price/Sale | 4.39 |
| Price/Book | 18.98 |
| Beta | 3.00 |
| EPS | 7.84 |
| EPS United States (ID:6, base:3382) | 24.33 |
Dividend growth streak
Amgen has raised their dividend 10.00 years in a row. This is above the 4.499729 year average in the 'Drug Manufacturers General' industry
Forward Annual Dividend Yield
Forward Annual Dividend Yield: Amgen has raised their dividend 3.42 years in a row. This is below the 42121.954600 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 3 Years
Compound Average Growth Rate 3 Years: Amgen has raised their dividend 10.01 years in a row. This is below the 23.957000 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 5 Years
Compound Average Growth Rate 5 Years: Amgen has raised their dividend 10.04 years in a row. This is below the 12.560500 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 10 Years
Compound Average Growth Rate 10 Years: Amgen has raised their dividend 16.31 years in a row. This is above the 10.207200 year average in the 'Drug Manufacturers General' industry
Payout Ratio
Payout Ratio: Amgen has raised their dividend 113.41 years in a row. This is below the 148.467900 year average in the 'Drug Manufacturers General' industry
Self funded year
Amgen years needed to self fund. This is below the 34.112811 year average in the 'Drug Manufacturers General' industry
Dividend growth streak
Amgen has raised their dividend 10.00 years in a row. This is above the 4.499729 year average in the 'Drug Manufacturers General' industry
Forward Annual Dividend Yield
Forward Annual Dividend Yield: Amgen has raised their dividend 3.42 years in a row. This is below the 42121.954600 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 3 Years
Compound Average Growth Rate 3 Years: Amgen has raised their dividend 10.01 years in a row. This is below the 23.957000 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 5 Years
Compound Average Growth Rate 5 Years: Amgen has raised their dividend 10.04 years in a row. This is below the 12.560500 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 10 Years
Compound Average Growth Rate 10 Years: Amgen has raised their dividend 16.31 years in a row. This is above the 10.207200 year average in the 'Drug Manufacturers General' industry
Payout Ratio
Payout Ratio: Amgen has raised their dividend 113.41 years in a row. This is below the 148.467900 year average in the 'Drug Manufacturers General' industry
Self funded year
Amgen years needed to self fund. This is below the 34.112811 year average in the 'Drug Manufacturers General' industry